Articles
| Open Access |
DOI: TARGETED THERAPY IN THE PALLIATIVE TREATMENT OF PLATINUM-RESISTANT RECURRENT OVARIAN CANCER COMPLICATED BY ASCITES
Sh.Sh.Shakhanova , Samarkand State Medical University, Uzbekistan J.A. Abdurakhmonov , Samarkand State Medical University, Uzbekistan N.M.Rakhimov , Samarkand Regional Interregional Hospice Centre, UzbekistanAbstract
Ascites in ovarian cancer can reach any volume. As a rule, a small effusion without clinical manifestations is not removed, it regresses against the background of systemic chemotherapy. In ovarian cancer ascites is rarely very large, but the abdomen can be huge due to the combination of several litres of fluid with a large mass of tumour. Ascites that interferes with normal life is necessarily evacuated. Due to the accumulation of fluid can cause shortness of breath and swelling of the legs, impaired breathing and nutrition - vomiting just eaten and drunk. In such situations, a laparocentesis must be performed.
Keywords
Platinum resistance, targeted therapy, ovarian cancer
References
Рахимов Н. М. и др. МЕХАНИЗМ РАЗВИТИЯ ПЕРИТОНЕАЛЬНОГО ЗЛОКАЧЕСТВЕННОГО АСЦИТА ПРИ РЕЦИДИВЕ РАКА ЯИЧНИКА //Клиническая и экспериментальная онкология. – 2020. – №. 4. – С. 45-49.
Anderson R. D. American Society of Hospital Pharmacists. ASHP statement on the use of medications for unlabeled uses //Am J Hosp Pharm. – 1992. – Т. 49. – №. 8. – С. 2-006
Bertozzi S. et al. Nanotechnologies in obstetrics and cancer during pregnancy: a narrative review //Journal of Personalized Medicine. – 2022. – Т. 12. – №. 8. – С. 1324
Cazzaniga M. E. et al. Metronomic chemotherapy //Cancers. – 2021. – Т. 13. – №. 9. – С. 2236.
Colombo N. et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease //Annals of Oncology. – 2019. – Т. 30. – №. 5. – С. 672-705.
Dzhurayev M. D. et al. Key Priorities For Immunohistochemical Testing In Predicting Cervical Cancer Recurrence //The American Journal of Medical Sciences and Pharmaceutical Research. – 2021. – Т. 3. – №. 06. – С. 87-93.
duBois A. et al. A Phase III //Randomized, Double-Blind Trial of Pazopanib Versus Placebo in Women Who Have Not Progressed After First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (AEOC): Results of an International Intergroup Trial (AGO-OVAR 16) American Society of Clinical Oncology. – 2013. – Т. 31.
Fountzilas E., Said R., Tsimberidou A. M. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits //Expert opinion on investigational drugs. – 2018. – Т. 27. – №. 2. – С. 155-162.
Green A. E., Rose P. G. Pegylated liposomal doxorubicin in ovarian cancer //International journal of nanomedicine. – 2006. – Т. 1. – №. 3. – С. 229.
Lee A. T. J., Jones R. L., Huang P. H. Pazopanib in advanced soft tissue sarcomas //Signal transduction and targeted therapy. – 2019. – Т. 4. – №. 1. – С. 16.
Oaknin A. et al. A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study. – 2012.
Gulia S. et al. Pazopanib and oral cyclophosphamide in women with platinum-resistant or-refractory epithelial ovarian cancer //JCO Global Oncology. – 2020. – Т. 6. – С. 542-547
Gupta S. et al. A phase II study of oral metronomic combination therapy in relapsed epithelial ovarian cancer. – 2013. Pandey A. et al. Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience //South Asian Journal of Cancer. – 2016. – Т. 5. – №. 02. – С. 059-062.
Perrone M. G. et al. Translational Theragnosis of Ovarian Cancer: where do we stand? //Current Medicinal Chemistry. – 2020. – Т. 27. – №. 34. – С. 5675-5715
Saiyed M. M., Ong P. S., Chew L. Off‐label drug use in oncology: a systematic review of literature //Journal of clinical pharmacy and therapeutics. – 2017. – Т. 42. – №. 3. – С. 251-258
Saidkulov B. et al. Recurrent ovarian cancer: mechanisms of development of peritoneal malignant ascites //European Journal of Molecular and Clinical Medicine. – 2020. – Т. 7. – №. 2. – С. 2423-2428.
17. Zhang Y. et al. The Efficacy and Safety of Pazopanib Plus Chemotherapy in Treating Recurrent or Persistent Ovarian Cancer: A Systematic Review and Meta-Analysis //American Journal of Clinical Oncology. – 2023. – Т. 46. – №. 6. – С. 25
Article Statistics
Copyright License
Copyright (c) 2023 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.